EPCAM and colorectal carcinoma: The ability of recombinant EpCAM BiTE protein to activate PBMC‐derived T cells was evaluated by adding unstimulated human primary CD3+ cells to a culture of human DLD colorectal carcinoma cells, which are known to express EpCAM on their surface (Karlsson et al, 2008).